Synthetic Biologics Developing Monoclonal Antibodies To Treat Acinetobacter Infections
Synthetic Biologics Inc., a developer of synthetic biologics and innovative medicines for serious diseases and unmet medical needs, today announced that it has initiated efforts to develop a monoclonal antibody (mAb) therapy for the treatment of acinetobacter infections.
